Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 24;13(9):2907.
doi: 10.3390/nu13092907.

The Impact of Highly Effective CFTR Modulators on Growth and Nutrition Status

Affiliations
Review

The Impact of Highly Effective CFTR Modulators on Growth and Nutrition Status

Rosara Bass et al. Nutrients. .

Abstract

Patients with cystic fibrosis (CF) are at increased risk of malnutrition and growth failure due to multiple factors as a result of suboptimal or absent function of the CFTR chloride channel protein. Dysfunctional CFTR contributes to increased energy expenditure, exocrine pancreatic insufficiency causing impaired dietary macronutrient digestion and absorption, intestinal dysbiosis, and impaired bile acid homeostasis. Poor nutritional status as a result of these mechanisms is associated with decreased lung function, worse clinical outcomes, and ultimately, increased mortality. Nutritional interventions addressing these mechanisms, such as pancreatic enzyme-replacement therapy and enteral caloric supplementation, have improved nutritional status and, by association, clinical outcomes. In the last decade, the advent of medications targeting defective CFTR proteins has revolutionized the care of patients with CF by reducing the overall impact of CFTR dysfunction. Below, we summarize the effects of highly effective CFTR modulators on nutritional status overall as well as specific factors including bile acid metabolism, pancreatic function, energy expenditure, and intestinal dysbiosis. The future of CF nutrition care will require a paradigm shift away from focusing on methods addressing CFTR dysfunction such as excess calorie provision and toward an individualized, holistic approach in the context of specific mutations and CFTR-directed therapy.

Keywords: CFTR corrector; CFTR modulator; nutrition.

PubMed Disclaimer

Conflict of interest statement

R.B. is supported by the Cystic Fibrosis Foundation Physician Training Program. J.N.B. and V.A.S. receive investigator-initiated grant funding from Vertex and Chiesi USA, Inc. for unrelated projects. V.A.S. has consulted for Abbvie, Inc., Abbott and Nestle Health Sciences. These funders had no role in any aspect of the creation, planning, or execution of the project.

References

    1. Rowe S.M., Miller S., Sorscher E.J. Cystic fibrosis. N. Engl. J. Med. 2005;352:1992–2001. doi: 10.1056/NEJMra043184. - DOI - PubMed
    1. Zeitlin P.L. Pharmacologic restoration of αδF508 CFTR-mediated chloride current. Kidney Int. 2000;57:832–837. doi: 10.1046/j.1523-1755.2000.00922.x. - DOI - PubMed
    1. McKone E.F., Emerson S.S., Edwards K.L., Aitken M.L. Effect of genotype on phenotype and mortality in cystic fibrosis: A retrospective cohort study. Lancet. 2003;361:1671–1676. doi: 10.1016/S0140-6736(03)13368-5. - DOI - PubMed
    1. Cystic Fibrosis Foundation . Patient Registry 2019 Annual Data Report. Cystic Fibrosis Foundation; Bethesda, MD, USA: 2020.
    1. Cuevas-Ocaña S., LaSelva O., Avolio J., Nenna R. The era of CFTR modulators: Improvements made and remaining challenges. Breathe. 2020;16:200016. doi: 10.1183/20734735.0016-2020. - DOI - PMC - PubMed

MeSH terms

Substances